REGMF (RemeGen Co) Moat Score: 4/10 (As of Jul. 11, 2026)


REGMF RemeGen Co Ltd REGMF
45 GF Score
Price $12.05
GF Value $27.14
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is RemeGen Co Moat Score?

RemeGen Co REGMF -6.23% 45 Moat Score is 4 as of Jul. 11, 2026. GuruFocus rates REGMF with a GF Score™ of 45/100 and a GF Value™ of $27.14 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,395 Biotechnology companies, RemeGen Co ranks better than 88.75% on this metric.

RemeGen Co has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

RemeGen Co has Narrow Moat: RemeGen has valuable intellectual property in biopharmaceuticals and some regulatory barriers due to drug approvals. However, the competitive landscape and high R&D costs limit its moat. The company has potential for growth, but its current market position and customer loyalty are not strong enough for a wider moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes RemeGen Co might have Narrow Moat - Discernible but modest moat.

RemeGen Co  (OTCPK:REGMF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

RemeGen Co Moat Score Related Terms

REGMF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, RemeGen Co's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Moat Score distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Moat Score falls into.


REGMF
45GF Score
RemeGen Co Ltd REGMF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
RemeGen Co (REGMF) has a Moat Score of 4 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, RemeGen Co ranks #157 out of 1395 companies in the Biotechnology industry, placing it in the top 11.3%.
Is RemeGen Co's Moat Score too high?
RemeGen Co's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. RemeGen Co's value of 4 is 100% above this industry median. Based on the distribution chart, RemeGen Co ranks #157 out of 1395 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RemeGen Co has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #157 out of 1395 companies for Moat Score. This places RemeGen Co in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. RemeGen Co's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (REGMF) is currently considered Possible Value Trap. The stock's GF Value™ is $27.14, compared to a current price of $12.05 — trading 55.6% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. RemeGen Co's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For RemeGen Co (REGMF), the current Moat Score is 4 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RemeGen Co (REGMF) Overvalued in 2026?

Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued. The current stock price of $12.05 is trading 55.6% below its estimated GF Value™ of $27.14. GuruFocus considers RemeGen Co to be Possible Value Trap.

Key valuation signals for REGMF:

  • Moat Score: 4
  • GF Value™: $27.14 vs. price of $12.05 (55.6% below fair value)
  • GF Score™: 45/100 with 6 warning signs
  • Industry Position: 100% above the Biotechnology median (#157 of 1395)

No single metric tells the full story. See the REGMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RemeGen Co Business Description

Address 58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
45GF Score

Get the complete analysis for REGMF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.05
Price
$27.14
GF Value